RU2622082C2 - Анализы и способы выбора режима лечения пациента с депрессией - Google Patents

Анализы и способы выбора режима лечения пациента с депрессией Download PDF

Info

Publication number
RU2622082C2
RU2622082C2 RU2014124121A RU2014124121A RU2622082C2 RU 2622082 C2 RU2622082 C2 RU 2622082C2 RU 2014124121 A RU2014124121 A RU 2014124121A RU 2014124121 A RU2014124121 A RU 2014124121A RU 2622082 C2 RU2622082 C2 RU 2622082C2
Authority
RU
Russia
Prior art keywords
folate
seq
depression
containing compound
snp
Prior art date
Application number
RU2014124121A
Other languages
English (en)
Russian (ru)
Other versions
RU2014124121A (ru
Inventor
Маурицио ФАВА
Джордж ПАПАКОСТАС
мл. Гарольд О. КОЧ
Девид КРОНЛЕЙДЖ
Original Assignee
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нестек С.А. filed Critical Нестек С.А.
Publication of RU2014124121A publication Critical patent/RU2014124121A/ru
Application granted granted Critical
Publication of RU2622082C2 publication Critical patent/RU2622082C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2014124121A 2011-11-14 2012-11-14 Анализы и способы выбора режима лечения пациента с депрессией RU2622082C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559541P 2011-11-14 2011-11-14
US61/559,541 2011-11-14
PCT/US2012/065084 WO2013074676A2 (en) 2011-11-14 2012-11-14 Assays and methods for selecting a treatment regimen for a subject with depression

Publications (2)

Publication Number Publication Date
RU2014124121A RU2014124121A (ru) 2015-12-27
RU2622082C2 true RU2622082C2 (ru) 2017-06-09

Family

ID=47279072

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014124121A RU2622082C2 (ru) 2011-11-14 2012-11-14 Анализы и способы выбора режима лечения пациента с депрессией

Country Status (13)

Country Link
US (2) US9540691B2 (cg-RX-API-DMAC7.html)
EP (1) EP2780467B1 (cg-RX-API-DMAC7.html)
JP (1) JP6285865B2 (cg-RX-API-DMAC7.html)
KR (1) KR102035877B1 (cg-RX-API-DMAC7.html)
CN (1) CN104053785A (cg-RX-API-DMAC7.html)
AU (1) AU2012340015B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014011491A2 (cg-RX-API-DMAC7.html)
CA (1) CA2855640C (cg-RX-API-DMAC7.html)
IL (1) IL232407B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN04226A (cg-RX-API-DMAC7.html)
MX (1) MX354547B (cg-RX-API-DMAC7.html)
RU (1) RU2622082C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013074676A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220213A1 (en) * 2022-05-11 2023-11-16 Higgins Evelyn Methods for providing a personalized therapeutic treatment regime for addictions

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
JP2016518816A (ja) * 2013-03-12 2016-06-30 ネステク ソシエテ アノニム うつに罹っている対象のための治療レジメンを選択するためのアッセイ及び方法
CN111643449A (zh) 2013-03-15 2020-09-11 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
US9610302B2 (en) * 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) * 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US20150250813A1 (en) * 2013-12-05 2015-09-10 Buriva, LLC Dietary supplement containing phospholipid-dha, folate, and n-acetyl-l-cysteine
RU2016138574A (ru) * 2014-03-05 2018-04-06 Такеда Фармасьютикал Компани Лимитед Способ лечения депрессии и депрессивного эпизода тяжелой степени
WO2015136446A1 (en) * 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
KR101588119B1 (ko) * 2014-05-16 2016-01-25 동아대학교 산학협력단 Ｓｌｃ6ａ3 유전자의 다형성 소위성과 이를 이용한 ｄｎａ 타이핑 키트 및 상기 유전자 관련 질병의 진단키트
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
MA40620A (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
CN105671130A (zh) * 2014-11-18 2016-06-15 武汉白原科技有限公司 一种心理性格检测试剂盒和方法
US20160203591A1 (en) * 2015-01-09 2016-07-14 Umm Al-Qura University System and process for monitoring the quality of food in a refrigerator
CN104655705B (zh) * 2015-02-12 2017-03-08 江苏省原子医学研究所 一种用毛细管电泳快速检测生物样本中儿茶酚氧甲基转移酶comt活性的方法
CN104789668A (zh) * 2015-04-10 2015-07-22 浙江博惠生物科技有限公司 一种叶酸代谢能力评估的检测位点rs1801394的检测PCR扩增引物和单碱基延伸引物
US11122997B2 (en) 2015-04-17 2021-09-21 Mayo Foundation For Medical Education And Research Modulating the aryl hydrocarbon receptor system to treat major depressive disorder
US20180137235A1 (en) * 2015-04-28 2018-05-17 Proove Biosciences, Inc. System and method for processing genotype information relating to opioid risk
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CA2987292A1 (en) * 2015-05-25 2016-12-01 Hunan Skyworld Biotechnologies Co. Ltd. Use of fluorescence for the quick and easy determination of s-adenosylmethionine, s-adenosylhomocysteine and homocysteine
US11313868B2 (en) 2016-06-14 2022-04-26 Board Of Regents, The University Of Texas System Methods of detecting anti-folic acid antibodies and uses thereof
US20200049722A1 (en) * 2016-09-26 2020-02-13 Precision Medicine Holdings Pty Ltd Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
CN107245527A (zh) * 2017-07-25 2017-10-13 重庆京因生物科技有限责任公司 Mtrr基因多态性快速检测的引物、分子信标、试剂盒及其检测方法
WO2019027568A1 (en) * 2017-08-02 2019-02-07 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc PORTABLE DEVICE AND APPLICATION FOR BEHAVIORAL CARRIER
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
CN108251522B (zh) * 2018-04-09 2020-11-27 江苏硕世生物科技股份有限公司 人类mthfr和mtrr基因检测试剂盒及其用途
CN108642138B (zh) * 2018-05-02 2021-11-30 广东药科大学 一种检测叶酸代谢相关基因遗传信息的方法及试剂盒
JP7398117B2 (ja) 2018-05-03 2023-12-14 デ，ロシェモント，エル．，ピエール 高速／低速電力サーバファームおよびサーバネットワーク
CA3102806A1 (en) 2018-06-05 2019-12-12 L. Pierre De Rochemont Module with high peak bandwidth i/o channels
CN108823299A (zh) * 2018-06-11 2018-11-16 苏州艾达康医疗科技有限公司 一种抑郁症用药相关基因的检测方法及试剂盒
WO2020051156A1 (en) * 2018-09-03 2020-03-12 Visby Medical, Inc. Devices and methods for antibiotic susceptibility testing
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
CN110148461B (zh) * 2019-06-26 2021-09-21 周建勋 用于多参数测量的模块切换系统
CN110693507A (zh) * 2019-08-30 2020-01-17 中国民用航空飞行学院 一种民航飞行学员心理健康测试和心理援助系统
CN111351945B (zh) * 2020-03-18 2021-04-23 东南大学 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用
US20220165379A1 (en) * 2020-11-24 2022-05-26 Genomind, Inc. Methods and systems for reporting patient- and drug-specific medical data
CN116103385B (zh) * 2021-11-11 2024-11-15 深圳理工大学 一种预测抑郁障碍患者对治疗反应的基因诊断试剂盒和系统
CN116298233A (zh) * 2022-03-16 2023-06-23 昱言科技(北京)有限公司 用于诊断双相障碍的生物标记物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2222329C2 (ru) * 1998-04-24 2004-01-27 Скариста Лимитед Лечение депрессии и фармацевтические препараты для этой цели
US20100304391A1 (en) * 2009-05-29 2010-12-02 Lombard Jay L Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US3837376A (en) 1971-06-01 1974-09-24 Metropolitan Pathology Labor I Blood serum collection tube and method
US4336185A (en) 1976-03-02 1982-06-22 Rohm And Haas Company Folic acid derivatives
US4120448A (en) 1977-06-08 1978-10-17 Baxter Travenol Laboratories, Inc. Centrifugal liquid processing apparatus with automatically positioned collection port
US4656035A (en) 1984-12-21 1987-04-07 University Of Tennessee Research Corporation Method of separating blood platelets
US4946773A (en) 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
WO1989006700A1 (en) 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
AU3694689A (en) 1988-04-28 1989-11-24 Mark H. Skolnick Amplified sequence polymorphisms (asps)
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5846710A (en) 1990-11-02 1998-12-08 St. Louis University Method for the detection of genetic diseases and gene sequence variations by single nucleotide primer extension
AU1248292A (en) 1990-12-06 1992-07-08 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6136540A (en) 1994-10-03 2000-10-24 Ikonisys Inc. Automated fluorescence in situ hybridization detection of genetic abnormalities
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5851770A (en) 1994-04-25 1998-12-22 Variagenics, Inc. Detection of mismatches by resolvase cleavage using a magnetic bead support
GB9410620D0 (en) 1994-05-26 1994-07-13 Univ Mcgill cDNA for human mehylenetetrahydrofolate reductase
US6566065B1 (en) 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5849483A (en) 1994-07-28 1998-12-15 Ig Laboratories, Inc. High throughput screening method for sequences or genetic alterations in nucleic acids
US5866337A (en) 1995-03-24 1999-02-02 The Trustees Of Columbia University In The City Of New York Method to detect mutations in a nucleic acid using a hybridization-ligation procedure
US5704888A (en) 1995-04-14 1998-01-06 Cobe Laboratories, Inc. Intermittent collection of mononuclear cells in a centrifuge apparatus
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP1012342A4 (en) 1997-09-10 2004-07-21 Univ Maryland METHOD FOR THE AMPLIFICATION OF DNA AND RNA PRODUCTS, STARTING FROM SPLIT PIECES DUE TO MISSING BASE PAIRINGS
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
DE69923200T2 (de) 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US6395481B1 (en) 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
US6730055B2 (en) 2000-03-09 2004-05-04 Gambro Inc. Extracorporeal blood processing methods and apparatus
US20020016293A1 (en) 2000-04-21 2002-02-07 Ratain Mark J. Flavopiridol drug combinations and methods with reduced side effects
DE10022510A1 (de) 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
US6355433B1 (en) 2000-06-02 2002-03-12 Dna Sciences, Inc. Determination of nucleotide sequence variations through limited primer extension
ES2291329T3 (es) 2000-07-18 2008-03-01 Dainippon Sumitomo Pharma Co., Ltd. Inhibidores de la recaptacion de serotonina.
US20030099960A1 (en) 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
CN1463291A (zh) 2001-04-19 2003-12-24 赛弗根生物系统股份有限公司 用质谱法和亲和标记物鉴定生物分子的特性
US20030100476A1 (en) 2001-05-11 2003-05-29 Weinberger Daniel R. Effect of COMT genotype on frontal lobe function
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
EP1425695A2 (en) 2001-08-13 2004-06-09 Beyong Genomics, Inc. Method and system for profiling biological systems
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
IL163645A0 (en) 2002-02-21 2005-12-18 Idgene Pharmaceuticals Ltd Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
US7241281B2 (en) 2002-04-08 2007-07-10 Thermogenesis Corporation Blood component separation method and apparatus
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US20030194711A1 (en) 2002-04-10 2003-10-16 Matthew Zapala System and method for analyzing gene expression data
WO2003091735A1 (en) 2002-04-23 2003-11-06 Millipore Corporation Sample preparation of biological fluids for proteomic applications
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
CA2415154C (en) 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
US20040203034A1 (en) 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US20050054688A1 (en) 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20050069936A1 (en) 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
EP1732610A2 (en) 2004-03-26 2006-12-20 Baylor University Targeted serotonin reuptake inhibitors
JP2005312435A (ja) 2004-03-29 2005-11-10 Kazuhito Rokutan うつ病の評価方法
US20060216737A1 (en) 2005-03-10 2006-09-28 John Bodeau Methods for multiplex amplification
US7972770B2 (en) 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
JP2009518035A (ja) 2005-12-06 2009-05-07 ザ ジェネラル ホスピタル コーポレイション 疼痛感受性および慢性化に関する診断法およびテトラヒドロビオプテリン関連障害に関する診断法
US20080064702A1 (en) 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008066769A2 (en) 2006-11-29 2008-06-05 Lohocla Research Corporation Genetic diagnosis of depression
US20090075827A1 (en) 2007-01-19 2009-03-19 Queensland University Of Technology Diagnostic methods and agents
US7947662B2 (en) 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
WO2009117122A2 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
WO2009131643A1 (en) 2008-04-21 2009-10-29 Monabio, Inc. Immunoassay for specific determination of s-adenosymethionine and analogs thereof in biological samples
EP2485747A4 (en) 2008-06-21 2013-10-23 Kenneth Blum CUSTOMIZATION DIRECTED BY THE DNA OF ANALGESIC COMPOUNDS AS A THERAPEUTIC MODALITY
WO2010060189A1 (en) 2008-11-03 2010-06-03 Newlab Clinical Research Inc. Allele-allele interactions of mthfr gene variants, and uses thereof in predicting disease risk
RU2012117898A (ru) 2009-09-30 2013-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Кофакторы и способы их применения индивидуумами
US20140088035A1 (en) * 2010-12-03 2014-03-27 The General Hospital Corporation Treating schizophrenia
KR20120092993A (ko) 2011-02-14 2012-08-22 지엘팜텍 주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
EP2691081A1 (en) 2011-03-28 2014-02-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Sustained-release injectable formulation
WO2012177746A1 (en) 2011-06-21 2012-12-27 Global Healthcare Focus, Llc Methods of preventing or treating disease states related to certain metabolic abnormalities
US20160058766A1 (en) * 2011-11-14 2016-03-03 Nestec S.A. Assays and methods for selecting a treatment regimen for a subject with depression
CA2855640C (en) * 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2222329C2 (ru) * 1998-04-24 2004-01-27 Скариста Лимитед Лечение депрессии и фармацевтические препараты для этой цели
US20100304391A1 (en) * 2009-05-29 2010-12-02 Lombard Jay L Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAVA MAURIZIO et al., Folate in depression: efficacy, safety, differences in formulations, and clinical issues, The Journal of Clinical Psychiatry Vol. 70, Suppl. 5, pp. 12-17, 2009. SEREN HAF ROBERTS et al., Folate Augmentation of Treatment - Evaluation for Depression (FolATED): protocol of a randomised controlled trial, BMC Psychiatry, Vol. 7, NO. 1, p. 65, 2007. MARK LUCOCK, Folic Acid: Nutritional Biochemistry, Molecular Biology, and Role in Disease Processes, Molecular Genetics and Metabolism Vol. 71, Issue 1-2, pp. 121-138, 2000. *
SJ LEWIS et al., Folic acid supplementation during pregnancy may protect against depression 21 months after pregnancy, an effect modified by MTHFR C677T genotype, European Journal of Clinical Nutrition Vol. 66, No. 1, pp. 97-103, 2011. ALEC COPPEN et al., Treatment of depression: time to consider folic acid and vitamin B12, Journal of Psychopharmacology Vol. 19, No. 1, pp. 59-65, 2005. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220213A1 (en) * 2022-05-11 2023-11-16 Higgins Evelyn Methods for providing a personalized therapeutic treatment regime for addictions

Also Published As

Publication number Publication date
MX2014005786A (es) 2014-08-27
KR102035877B1 (ko) 2019-10-23
US20130267523A1 (en) 2013-10-10
CN104053785A (zh) 2014-09-17
IL232407B (en) 2019-03-31
CA2855640A1 (en) 2013-05-23
NZ624231A (en) 2016-10-28
EP2780467B1 (en) 2018-10-17
WO2013074676A3 (en) 2013-08-15
IN2014DN04226A (cg-RX-API-DMAC7.html) 2015-05-22
EP2780467A2 (en) 2014-09-24
US20130172361A1 (en) 2013-07-04
US9540691B2 (en) 2017-01-10
WO2013074676A2 (en) 2013-05-23
JP6285865B2 (ja) 2018-02-28
IL232407A0 (en) 2014-06-30
MX354547B (es) 2018-03-09
BR112014011491A2 (pt) 2017-05-09
RU2014124121A (ru) 2015-12-27
JP2015508281A (ja) 2015-03-19
AU2012340015A1 (en) 2014-05-22
CA2855640C (en) 2020-03-10
AU2012340015B2 (en) 2017-09-21
US9546401B2 (en) 2017-01-17
HK1202590A1 (en) 2015-10-02
KR20140100524A (ko) 2014-08-14

Similar Documents

Publication Publication Date Title
RU2622082C2 (ru) Анализы и способы выбора режима лечения пациента с депрессией
Sharma et al. Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity
Aquilante et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
Makris Hyperhomocysteinemia and thrombosis
TW201437635A (zh) 選擇用於患憂鬱症個體之療法之分析及方法
Claes et al. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes
US20180275149A1 (en) Method for predicting a subject's response to valproic acid therapy
Nibali et al. Vitamin D receptor polymorphism (− 1056 Taq‐I) interacts with smoking for the presence and progression of periodontitis
Serretti et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression
Mischoulon et al. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment
Reinhardt et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease
WO2015136446A1 (en) Methods for selecting antidepressant drug therapy to treat depression
Kaiser et al. Parkinson’s disease causality and heterogeneity: a proteogenomic view
Moreno et al. Association study of genotype by depressive response during acute tryptophan depletion in subjects recovered from major depression
Hendrie et al. Homocysteine levels and dementia risk in Yoruba and African Americans
Nilsson et al. Survival in a large elderly population of patients with dementia and other forms of psychogeriatric diseases
JP2009518035A (ja) 疼痛感受性および慢性化に関する診断法およびテトラヒドロビオプテリン関連障害に関する診断法
HK1202590B (en) Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
NZ624231B2 (en) Assays and methods for selecting a treatment regimen for a subject with depression
US20160058766A1 (en) Assays and methods for selecting a treatment regimen for a subject with depression
Ye et al. The folate hydrolase 1561C> T polymorphism is associated with depressive symptoms in Puerto Rican adults
JP2011125218A (ja) 糖尿病患者のフェニルアラニン誘導体系薬物感受性予測方法
Bader et al. An atypical phenotype is a risk factor for higher mortality in Alzheimer’s disease
Iskandar Examining the use of biologic therapies in the management of psoriasis: understanding drug utilisation, impact on quality of life and drug survival

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
PC41 Official registration of the transfer of exclusive right

Effective date: 20180116

PD4A Correction of name of patent owner